Literature DB >> 28218580

Circulating cathelicidin LL-37 in adult patients with pulmonary infectious diseases.

Karol Majewski1, Paulina Żelechowska, Ewa Brzezińska-Błaszczyk.   

Abstract

PURPOSE: The antimicrobial peptide cathelicidin LL-37 plays a role in the immune response in the course of lung infections; however, the exact role of LL-37 in defense mechanisms against bacteria within the respiratory tract is has not been precisely described. The aim of our study was to evaluate LL-37 concentrations in the serum of pulmonary tuberculosis (TB) patients, patients with pneumonia caused by Gram-positive and Gram-negative bacteria and to compare them with those of healthy subjects.
METHODS: Thirty TB patients, 30 patients with pneumonia caused by Gram-positive bacteria, 30 patients with pneumonia caused by Gram-negative bacteria, and 30 healthy control subjects were enrolled in the study. Serum LL-37 concentration was measured using an enzyme-linked immunosorbent assay (ELISA).
RESULTS: The mean (± SEM) LL-37 concentration in patients with TB (13.94±5.13 ng/mL) was significantly higher than that in patients with Gram-positive bacteria-induced pneumonia (7.87±4.58 ng/mL, P=0.00077), in patients with Gram-negative bacteria-induced pneumonia (10.27±3.60 ng/mL, P=0.00730), and in control healthy subjects (1.75±0.71 ng/mL, P=0.00004).
CONCLUSION: Our data suggest that cathelicidin LL-37 is an important element of host defense in the course of bacterial diseases within the respiratory tract, particularly when the infection is caused by an intracellular pathogen.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28218580     DOI: 10.25011/cim.v40i1.28052

Source DB:  PubMed          Journal:  Clin Invest Med        ISSN: 0147-958X            Impact factor:   0.825


  9 in total

1.  Human cathelicidin LL-37 - Does it influence the homeostatic imbalance in mental disorders?

Authors:  Elzbieta Kozlowska; Adam Wysokinski; Karol Majewski; Justyna Agier; Aleksandra Margulska; Ewa Brzezinska-Blaszczyk
Journal:  J Biosci       Date:  2018-06       Impact factor: 1.826

2.  Human serum triggers antibiotic tolerance in Staphylococcus aureus.

Authors:  Elizabeth V K Ledger; Stéphane Mesnage; Andrew M Edwards
Journal:  Nat Commun       Date:  2022-04-19       Impact factor: 17.694

3.  Cathelicidin LL-37 Affects Surface and Intracellular Toll-Like Receptor Expression in Tissue Mast Cells.

Authors:  Justyna Agier; Ewa Brzezińska-Błaszczyk; Paulina Żelechowska; Magdalena Wiktorska; Jacek Pietrzak; Sylwia Różalska
Journal:  J Immunol Res       Date:  2018-02-19       Impact factor: 4.818

4.  Plasma cathelicidin and longitudinal lung function in current and former smokers.

Authors:  Robert M Burkes; Jacquie Astemborski; Allison A Lambert; Todd T Brown; Robert A Wise; Gregory D Kirk; M Bradley Drummond
Journal:  PLoS One       Date:  2019-02-27       Impact factor: 3.752

5.  Human cathelicidin antimicrobial peptide suppresses proliferation, migration and invasion of oral carcinoma HSC-3 cells via a novel mechanism involving caspase-3 mediated apoptosis.

Authors:  Xi Chen; Shenying Ji; Jia Si; Xiangyu Zhang; Xiaoyan Wang; Yong Guo; Xianqiong Zou
Journal:  Mol Med Rep       Date:  2020-10-23       Impact factor: 2.952

6.  High Vitamin D Concentrations Restore the Ability to Express LL37 by M. tuberculosis-Infected Human Macrophages.

Authors:  María Teresa Herrera; Esmeralda Juárez; Silvia Guzmán-Beltrán; Martha Torres; Victor Adrián Luna-Morales; Leonardo Daniel Villalana-Alvarez; Yolanda González
Journal:  Biomolecules       Date:  2022-02-07

7.  Evaluation of circulating serum cathelicidin levels as a potential biomarker to discriminate between active and latent tuberculosis in Uganda.

Authors:  Ester Lilian Acen; David Patrick Kateete; William Worodria; Ronald Olum; Moses L Joloba; Mudarshiru Bbuye; Irene Andia Biraro
Journal:  PLoS One       Date:  2022-08-26       Impact factor: 3.752

8.  Bronchoalveolar Lavage and Plasma Cathelicidin Response to 25-Hydroxy Vitamin D Supplementation: A Pilot Study.

Authors:  Emily C Sanders; Robert M Burkes; Jason R Mock; Todd T Brown; Robert A Wise; Nadia N Hansel; Mark C Liu; M Bradley Drummond
Journal:  Chronic Obstr Pulm Dis       Date:  2021-07-28

9.  The anti-microbial peptide LL-37/CRAMP levels are associated with acute heart failure and can attenuate cardiac dysfunction in multiple preclinical models of heart failure.

Authors:  Qiulian Zhou; Li-Long Pan; Ruicong Xue; Gehui Ni; Yi Duan; Yuzheng Bai; Chao Shi; Zhengnan Ren; Chengfei Wu; Guoping Li; Birgitta Agerberth; Joost Pg Sluijter; Jia Sun; Junjie Xiao
Journal:  Theranostics       Date:  2020-05-15       Impact factor: 11.556

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.